ARTICLE | Distillery Therapeutics
Therapeutics: CREB binding protein (CREBBP; CBP); E1A binding protein p300 (EP300; p300); interleukin-17A (IL-17A)
September 17, 2015 7:00 AM UTC
Patient sample studies suggest inhibiting CREBBP and EP300 could help treat ankylosing spondylitis, psoriatic arthritis and other autoimmune diseases involving IL-17A-mediated inflammation. In culture...